The Effect of Combined Use of Anti-fibrotic Agent With Platelet Rich Plasma on Skeletal Muscle Healing After Acute Injuries
PRP, Losartan, Muscle Injury
About this trial
This is an interventional treatment trial for PRP
Eligibility Criteria
Inclusion Criteria: Adult age. (18 - 40 year old). Clinically diagnosed acute skeletal muscle injury with maximum 3 days duration and ultrasonographically confirmed grade II according to Woodhouse et al. Understanding the study and accepting the participation Exclusion Criteria: Any connective tissue disease (e.g. rheumatoid arthritis, systemic lupus erythematous, etc.) Hypertension or hypotension Diabetes mellitus Any cardiac or pulmonary disease NSAIDs use in less than a week prior to the beginning of the study. Muscle injuries requiring surgical interference. No detectable injury ultrasonographically. Anemia Thrombocytopenia or any platelet disorder. Pregnancy or lactation. Local infection
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
10 patients with acute skeletal muscle injury underwent PRP injection
10 patients with acute skeletal muscle injury underwent PRP injection and oral LOSARTAN
Patients with acute skeletal muscle injury received a single ultrasound guided local PRP injection in the site of injury in day 1 or 2 of the injury.
Patients with acute skeletal muscle injury received a single ultrasound guided local PRP injection in day 1 or 2 of injury in addition to administration of oral (50mg LOSARTAN /day) from day 5 to day 30.